Prevalence and initiation of statin therapy in the oldest old-a longitudinal population-based study.
Dose
Incidence
Older people
Pharmacoepidemiology
Prevalence
Register
Statins
Journal
European journal of clinical pharmacology
ISSN: 1432-1041
Titre abrégé: Eur J Clin Pharmacol
Pays: Germany
ID NLM: 1256165
Informations de publication
Date de publication:
Sep 2022
Sep 2022
Historique:
received:
07
12
2021
accepted:
24
05
2022
pubmed:
6
7
2022
medline:
13
8
2022
entrez:
5
7
2022
Statut:
ppublish
Résumé
To investigate the prevalence and initiation of statins as well as treatment intensity in the oldest old, with younger olds as a reference. A population-based cohort was used, including record-linked data from the Total Population Register, the Swedish Prescribed Drug Register, and the Swedish Patient Register. In each year over the study period (2009-2015), statin use was described in individuals 85 years or older and 65-84 years of age, and initiation rates were calculated among individuals with no statin treatment during a preceding 3-year period. A total of 1,764,836 individuals ≥ 65 years in 2009, increasing to 2,022,764 in 2015, were included in the analyses. In individuals 85 years or older, the prevalence of statin therapy increased from 11% in 2009 to 16% in 2015, the corresponding initiation rates being 1.3% and 1.7%, respectively. Corresponding prevalence and incidence figures in 65-84-year-olds were 23 to 25% and 3.0 to 3.3%, respectively. Overall, the proportion of individuals initiating statin with high-intensity treatment (atorvastatin ≥ 40 mg or rosuvastatin ≥ 20 mg) in the oldest old increased from 1 to 36% during the study period, and a similar increase was seen in the younger age group. Over the study years, the presence of an established indication for statin treatment varied between 70 and 76% in the oldest old and between 30 and 39% in the younger olds. Prevalence and initiation of statin therapy are increasing among the oldest old, despite the fact that randomized controlled trials focusing on this age group are lacking and safety signals are difficult to detect.
Identifiants
pubmed: 35788725
doi: 10.1007/s00228-022-03343-w
pii: 10.1007/s00228-022-03343-w
pmc: PMC9365718
doi:
Substances chimiques
Hydroxymethylglutaryl-CoA Reductase Inhibitors
0
Rosuvastatin Calcium
83MVU38M7Q
Atorvastatin
A0JWA85V8F
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1459-1467Subventions
Organisme : Forskningsrådet om Hälsa, Arbetsliv och Välfärd
ID : 2017-01764
Informations de copyright
© 2022. The Author(s).
Références
Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC, Jr., Watson K, Wilson PW (2014) 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63 (25 Pt B):2889–2934. https://doi.org/10.1016/j.jacc.2013.11.002
Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL et al (2016) 2016 European Guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis 252:207–274. https://doi.org/10.1016/j.atherosclerosis.2016.05.037
doi: 10.1016/j.atherosclerosis.2016.05.037
pubmed: 27664503
Serruys PW, de Feyter P, Macaya C, Kokott N, Puel J, Vrolix M, Branzi A, Bertolami MC, Jackson G, Strauss B, Meier B (2002) Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA 287(24):3215–3222
doi: 10.1001/jama.287.24.3215
Heart Protection Study Collaborative Group (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360(9326):7–22. https://doi.org/10.1016/s0140-6736(02)09327-3
doi: 10.1016/s0140-6736(02)09327-3
The long term intervention with pravastatin in ischaemic disease (lipi) study group (1998) Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339 (19):1349-1357. https://doi.org/10.1056/nejm199811053391902
Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 333(20):1301–1307. https://doi.org/10.1056/nejm199511163332001
Scandinavian Simvastatin Survival Study Group (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344(8934):1383–1389
Collaboration CTT (2019) Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet 393(10170):407–415. https://doi.org/10.1016/s0140-6736(18)31942-1
doi: 10.1016/s0140-6736(18)31942-1
Gencer B, Marston NA, Im K, Cannon CP, Sever P, Keech A, Braunwald E, Giugliano RP, Sabatine MS (2020) Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials. Lancet 396(10263):1637–1643. https://doi.org/10.1016/s0140-6736(20)32332-1
doi: 10.1016/s0140-6736(20)32332-1
pubmed: 33186535
pmcid: 8015314
Sundvall H, Fastbom J, Wallerstedt SM, Vitols S (2019) Use of statins in the elderly according to age and indication-a cross-sectional population-based register study. Eur J Clin Pharmacol 75(7):959–967. https://doi.org/10.1007/s00228-019-02645-w
doi: 10.1007/s00228-019-02645-w
pubmed: 30826850
Ludvigsson JF, Almqvist C, Bonamy AK, Ljung R, Michaelsson K, Neovius M et al (2016) Registers of the Swedish total population and their use in medical research. Eur J Epidemiol 31(2):125–136. https://doi.org/10.1007/s10654-016-0117-y
doi: 10.1007/s10654-016-0117-y
pubmed: 26769609
Ludvigsson JF, Otterblad-Olausson P, Pettersson BU, Ekbom A (2009) The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research. Eur J Epidemiol 24(11):659–667. https://doi.org/10.1007/s10654-009-9350-y
doi: 10.1007/s10654-009-9350-y
pubmed: 19504049
pmcid: 2773709
Wettermark B, Hammar N, Fored CM, Leimanis A, Otterblad Olausson P, Bergman U et al (2007) The new Swedish Prescribed Drug Register–opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf 16(7):726–735. https://doi.org/10.1002/pds.1294
doi: 10.1002/pds.1294
pubmed: 16897791
Ludvigsson JF, Andersson E, Ekbom A, Feychting M, Kim JL, Reuterwall C et al (2011) External review and validation of the Swedish national inpatient register. BMC Public Health 11:450. https://doi.org/10.1186/1471-2458-11-450
doi: 10.1186/1471-2458-11-450
pubmed: 21658213
pmcid: 3142234
ACC/AHA (2013) Guidelines for ATC classification and DDD assignment 2013. In: ed. WHO Collaborating Centre for Drug Statistic Methodology
Wallerstedt SM, Fastbom J, Johnell K, Sjöberg C, Landahl S, Sundström A (2013) Drug treatment in older people before and after the transition to a multi-dose drug dispensing system–a longitudinal analysis. PLoS ONE 8(6):e67088. https://doi.org/10.1371/journal.pone.0067088
doi: 10.1371/journal.pone.0067088
pubmed: 23826197
pmcid: 3691131
Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P (2014) 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2889–2934. https://doi.org/10.1016/j.jacc.2013.11.002
Bertolotti M, Franchi C, Rocchi MB, Miceli A, Libbra MV, Nobili A et al (2017) Prevalence and Determinants of the Use of Lipid-Lowering Agents in a Population of Older Hospitalized Patients: the Findings from the REPOSI (REgistro POliterapie Societa Italiana di Medicina Interna) Study. Drugs Aging 34(4):311–319. https://doi.org/10.1007/s40266-017-0448-8
doi: 10.1007/s40266-017-0448-8
pubmed: 28299634
Ofori-Asenso R, Ilomäki J, Tacey M, Zomer E, Curtis AJ, Bell JS et al (2018) Patterns of statin use and long-term adherence and persistence among older adults with diabetes. J Diabetes 10(9):699–707. https://doi.org/10.1111/1753-0407.12769
doi: 10.1111/1753-0407.12769
pubmed: 29658177
Rodriguez F, Maron DJ, Knowles JW, Virani SS, Lin S, Heidenreich PA (2017) Association Between Intensity of Statin Therapy and Mortality in Patients With Atherosclerotic Cardiovascular Disease. JAMA cardiology 2(1):47–54. https://doi.org/10.1001/jamacardio.2016.4052
doi: 10.1001/jamacardio.2016.4052
pubmed: 27829091
Hartz I, Sakshaug S, Furu K, Engeland A, Eggen AE, Njølstad I, Skurtveit S (2007) Aspects of statin prescribing in Norwegian counties with high, average and low statin consumption - an individual-level prescription database study. BMC Clin Pharmacol 7:14. https://doi.org/10.1186/1472-6904-7-14
doi: 10.1186/1472-6904-7-14
pubmed: 18053228
pmcid: 2234392